"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- The primary objective is to obtain a RCB rate of 0-1 in at least 66%
研究概览
简要总结
The purpose of this study is to evaluate a novel neoadjuvant regimen for invasive breast carcinoma by using the MD Anderson residual cancer burden score.To prospectively evaluate the utility of the PET scan to guide the neoadjuvant treatment and the utility of the Oncotype test as a stratifier for treatment decisons in ER+/Her2- patients. To evaluate the clinical anti-tumor activity of neoadjuvant hormonal therapy in ER+/Her2 negative patients. To evaluate the prognostic factors associated associated with pathological response as measured by the residual cancer burden tool.
详细描述
Treatment propose of TEC-NAX for the triple negatives and for the Her2+ cases. For the Er+/Her2- cases, we propose to use the PET scan to guide therapy after the first course of TEC. Those who drop in SUV≤5%, will have their treatment modified by using the Oncotype test. Those Her2 negative patients whose response to the first 4 courses of induction TEC is less than a complete remission, will have their tretment changed to a second line regimen, Navelbine-Avastin-Xeloda(NAX), with the intention of capturing a better response prior to surgery. Those who are Her2+ will initially also receive TEC but subsequent therapy will include Trastuzumab(Herceptin) whether thet respond wellor not to TEC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Previously untreated (no chemotherapy, hormonal or radiation therapy)invasive breast cancer.
- •Diagnosis of invasive ductal or lobular breast cancer plus or minus DCIS. Inflammatory carcinoma will also be elegible.
- •Age≥ 18 years
- •Only female patients are eligible
- •Tumor≥ 1.0cm by MRI and/or sonographic or clinical exam measurements. If the tumor is <1.0 but the patient has biopsy proven lymph node metastasis, she will also be considered eligible.Although only tumors≥2cm are consideredmeasurable by RECIST criteria, we will nevertheless include tumors≥1cm since the primary endpoint is pathological CR rate.
- •Performance status ECOG≤2 or Karnofsky≥ 50%
- •Peripheral neuropathy≤ grade 1
- •Hematologic (minimal values):Absolute Neutrophil count≥1,500/mm³; Hemoglobin≥8.0g/dl; Paltelet count≥100,000/mm³
- •Hepatic; Total bilirubin≤ULN AST and ALT and ALP do not have to be within the range. In determining eligibility the more abnormal of the two values(AST or ALT) should be use as per protocol table on p.24of
- •Women of childbearing potential must have a negative pregnancy test
- •Men and women of childbearing potential must be willing to consent to use effective contraception while on treatment and for at least 3 months thereafter.
- •Renal;urine protein:creatinine(UPC)ratio1.0 at screening or urine dipstick for proteinuria<2+(patients discovered to have˃/=2+ protinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate</=1g of protein in 24 hrs to be elegible
排除标准
- •Pregnant or breast feeding patients are excluded
- •Patients with second malignancies with expected survival<5 years
- •Previous chemotherapy with Taxanes,Anthracyclines or Cyclophosphamide.
- •Patientes with history of severe hypersensitivity reaction to Taxotere(Docetaxel)or other drugs formulated with polysorbate
- •Pure DCIS diagnoses are not elegible
- •Special histologies with favorable prognosis such as mucinous, tubular are not elegible
- •Patients with reduced ejection fraction<50% are not eligible
- •Patients with tumors<1.0cm unless biopsy proven axillary node metastasis present.
- •Cardiac thrombotic events in the past 12 months
- •Stroke or transient ischemic attacks (TIA) within 12 months
- •poorly controlled hypertension defined as persistent blood pressure elevation˃150 systolic and/or 100 diastolic not responsive to medications.
- •GI condition that increases risk of perforation within 6 months of study
- •Any serious non-healing wound, ulcer, or bone fracture.
- •No minor surgical procedure within 7 days of study entry or major surgery within 28 days of study entry or anticipation of need for major surgical procedure during the course of the study.
- •Significant vascular disease such as symptomatic peripheral vascular disease.
- •Any evidence of bleeding diathesis or coagulopathy.
研究组 & 干预措施
ER- (Triple Neg. and ER- PR+ Her 2 -)
Experimental chemotherapy using neoadjuvant approach
干预措施: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab (Drug)
Her 2 +
Experimental chemotherapy using neoadjuvant approach
干预措施: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab (Drug)
ER + (ER+ PR+ Her 2- / ER+ PR- Her 2 -)
Experimental chemotherapy using neoadjuvant approach
干预措施: Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab (Drug)
结局指标
主要结局
The primary objective is to obtain a RCB rate of 0-1 in at least 66%
时间窗: 2 years
The primary objective is to raise the RCB rate of 0-1 to ≥40%. the startegy of using Oncotype test to guide NAC therapy will be considered encouraging for future testing if we are able to achieve this goal.
次要结局
未报告次要终点
研究者
Fernando Cabanillas
Hematolgist-Oncologist
Auxilio Mutuo Cancer Center